摘要
目的:探讨慢性阻塞性肺疾病(COPD)稳定期采用吸入舒利迭治疗的临床疗效。方法:随机抽取本院收治的稳定期COPD患者68例,分成对照组33例和观察组35例,其中对照组均给予祛痰剂(如氨溴索胶囊)、茶碱缓释片进行常规口服治疗,观察组均在常规治疗的基础上加用舒利迭吸入配合治疗,两组疗程均为1年,对两组患者的临床疗效进行对比分析。结果:治疗1年后,观察组患者的呼吸困难程度明显好转,且临床症状评分下降显著,两组比较差异有统计学意义(P<0.05)。同时,治疗后观察组患者的FEV1(即第一秒用力呼气量)、FEV1/FVC(%)(即1秒用力呼气量占肺活量百分比)和FEV1占预计值百分比(%)增加较明显,差异有统计学意义(P<0.05)。而对照组治疗前后上述数据却无明显改变,差异无统计学意义(P>0.05)。结论:COPD稳定期患者采用吸入舒利迭治疗效果明显,且用药安全,值得临床推广。
Objective： To investigate the clinical curative effect of seretide in treatment of chronic obstructive pulmonary disease （ COPD ） in stable phase.Method： 68 patients who had be attacked by a disease of COPD in stable phase from our hospital were randomly salected and divided into control group （ 33 cases ） and observation group （ 35 cases ） . The control group were given an expectorant such as the ambroxol hydrochloride capsules and theophylline sustained-release tablets for conventional oral treatment.The observation group patients added Seretide inhalation treatment on the basis of control group. The clinical efficacy of the two groups were compared after treatment for one year. Result： After one year treatment, the degree of dyspnea improved obviously and the clinical symptom score decreased significantly of the observation group （ P〈0.05 ） .At the same time, FEV1 （ the forced expiratory volume in I second ）, FEV1/FVC （ % ） （ forced expiratory volume in 1 second for FVC% ） and FEV1 percentage of predicted value （ % ） of the patients in the observation group after treatment increased significantly （ P〈0.05 ）, while the control group was no statistical significance （ P〉0.05 ） . Conclusion： Inhaling Seretide is sure and safe in treatment of COPD patients in stable phase, worthy of clinical application.
出处
《中国医学创新》
CAS
2013年第29期25-27,共3页
Medical Innovation of China
关键词
稳定期
慢性阻塞性肺疾病
舒利迭
疗效
Stable
Chronic obstructive pulmonary disease
Seretide
Curative effect of seretide
